Will Flanders widen pneumococcal vaccination after four child deaths?
Flanders is assessing a switch to a broader childhood pneumococcal vaccine after four children died from invasive infections caused by serotype 12F since 2025, according to VRT NWS and the Flemish Department of Care.
Four child deaths make the gap between Belgium’s expert recommendation and Flanders’ publicly funded vaccine programme an urgent health-policy issue. Parents must currently choose between the established free PCV13 schedule and broader, generally self-funded PCV20 protection.
The is evaluating a switch to a broader childhood pneumococcal vaccine after four children in died from invasive infections caused by serotype 12F since the beginning of 2025. reported that two babies died in 2025 and two more young children in the first half of 2026. The bacterial variant responsible is not covered by the 13-valent vaccine currently supplied free through the Flemish childhood programme.
For parents in , the immediate difficulty is that two levels of protection now coexist. Babies routinely receive three free doses of PCV13 through , a doctor or a paediatrician. PCV20, which covers seven additional pneumococcal serotypes including 12F, is available on prescription but is not generally reimbursed for children and requires four doses. That leaves families considering the broader vaccine to discuss both its medical relevance and its cost with a clinician.
Pneumococci commonly inhabit the nose and throat without causing illness. In rare cases, however, the bacteria invade normally sterile parts of the body and cause pneumonia, meningitis or sepsis. The identifies children under two, older people and people with weakened immunity as groups at greater risk of severe disease. Urgent medical assessment remains essential when a child becomes seriously unwell; vaccination reduces risk but does not replace diagnosis and treatment.
The present concern is not evidence that PCV13 has stopped working against its intended targets. In its public explanation, the Department said the vaccine “works well” and that the serotypes it covers have been strongly suppressed among young children. The problem is serotype replacement: as vaccine-covered strains decline, other variants can account for a larger share of disease. Serotype 12F is among the additional types covered by PCV20.
’s recommended PCV20 for routine childhood vaccination in April 2025. Its preferred schedule uses four doses, broadening protection but adding an appointment and increasing procurement costs. The noted in July 2026 that the communities had not yet implemented that advice and were still using three PCV13 doses. Childhood vaccination is organised by Belgium’s communities, so the federal expert recommendation does not itself change what or its French-speaking counterpart ONE supplies.
That division of responsibility explains the apparently conflicting messages. The ’s clinical perspective favours wider serotype coverage. The says it is examining the financial and organisational consequences through a health-economic assessment while monitoring infections and circulating strains. In federal parliament in November 2025, Health Minister Frank Vandenbroucke described PCV13 as “an excellent vaccine” pending that work, while confirming that implementation belongs to the communities.
The European context supports vaccination while leaving product choices largely national or regional. The says childhood immunisation is the most effective public-health measure against invasive pneumococcal disease and can also protect unvaccinated people by reducing circulation of covered strains. It cautions that surveillance systems differ across Europe, making direct comparisons between countries difficult.
There is nevertheless a sign that Flemish policy is moving. The Department of Care’s procurement page lists an open procedure for PCV20 supplies for the Flemish immunisation programme in 2027, with bids due on 10 September 2026. That indicates concrete preparation, although it does not by itself establish a start date, final schedule or eligibility rules.
Families should not postpone the vaccines already offered while awaiting a policy decision. The Department advises parents who are considering switching from PCV13 to PCV20—particularly when a child has medical risk factors—to speak with their doctor or . The next decisive information will be the outcome of the economic evaluation, the 2027 procurement process and updated surveillance showing whether serotype 12F continues to rise.
Impact
Regional — The decision directly concerns babies and young children in Flanders because the Flemish Community purchases the vaccines distributed through Kind en Gezin, doctors and paediatricians.
What it means for you
Parents of babies and young children in Flanders should check which pneumococcal vaccine their child is receiving and discuss PCV13 versus PCV20 with their doctor or paediatrician. The current public programme provides three PCV13 doses free of charge; broader PCV20 protection requires four childhood doses and is generally self-funded. Families considering PCV20 should ask about the complete schedule and total cost before changing course. The key policy date to watch is 2027, for which Flanders has opened PCV20 procurement, but no final publicly funded switch is stated in the article.
Opposing perspectives
- Belgian Superior Health Council and paediatric specialists
The federal expert body recommends PCV20 in the routine childhood schedule because its wider coverage includes serotype 12F and six other types absent from PCV13. This clinical framing prioritises the broadest available protection as disease patterns shift.
- Flemish Department of Care and programme managers
The Department stresses that PCV13 “works well” against the 13 types it targets and remains a valuable vaccine. It supports examining PCV20 but says a programme-wide switch must account for cost, procurement, an extra dose and operational feasibility.
Who, where and what
Key people, places and terms in this story
Belgian region assessing broader publicly funded pneumococcal vaccination for children.
Country in which expert vaccination advice and community-level funding decisions apply.
News organisation cited for reporting the four child deaths and vaccination debate.
Federal parliament whose Health Committee record is included among the article’s sources.
Flemish child and family service through which publicly funded childhood vaccines are distributed.
Show the full library (14)
Belgian region assessing broader publicly funded pneumococcal vaccination for children.
Country in which expert vaccination advice and community-level funding decisions apply.
Future vaccination programme for which Flanders has opened PCV20 procurement.
News organisation cited for reporting the four child deaths and vaccination debate.
Flemish child and family service through which publicly funded childhood vaccines are distributed.
Federal parliament whose Health Committee record is included among the article’s sources.
Flemish authority providing disease information and managing vaccine procurement.
Belgian expert body that recommended routine childhood PCV20 vaccination in April 2025.
Source on the Belgian basic vaccination schedule for infants and children.
European public-health agency cited for background on pneumococcal disease.
Bacterium responsible for pneumococcal infections and comprising more than 90 serotypes.
Thirteen-valent vaccine currently provided free to children under two in Flanders.
Twenty-valent vaccine covering serotype 12F and under consideration for the Flemish programme.
Pneumococcal serotype linked to the reported child deaths and covered by PCV20 but not PCV13.
Sources & evidence
- View sourceVRT NWSPrimaryprimary· vrtnws.be· 11 August 2026Retrieved 25 August 2026· 52 days ago· Dated
- View sourceFlemish Department of Care — pneumococcal infectionofficial· departementzorg.beRetrieved 25 August 2026
- View sourceFlemish Department of Care — vaccine procurementofficial· departementzorg.be· 11 August 2026Retrieved 25 August 2026· 52 days ago· Dated
- View sourceBelgian Centre for Pharmacotherapeutic Informationcorroborating· r.cbip.be· 1 July 2026Retrieved 25 August 2026· 93 days ago· Dated
Related topics
Related to this story
Pulse Insight — This topic connects to 10 associations and 2 funding programmes through the Flanders ecosystem.
Live connections from the Belgium Impulse ecosystem — not recommendations.
This briefing was prepared with AI assistance and reviewed by a Belgium Impulse editor before publication. methodology.